Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice

Journal of Nutrition

Volumn 139, Issue 3, 2009, Pages 598-602

  Wang, Shuhui ^a   Weite, Thomas ^a,e   Fang, Hao ^a,e   Chang, Gwong Jen J ^b   Born, Willi K ^c   O'Brien, Rebecca L ^c   Sun, Buxiang ^d   Fujii, Hajime ^d   Kosuna, Ken Ichi ^d   Wang, Tian ^a,e  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d Amino Up Chemical Co   (Japan)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE HEXOSE CORRELATED COMPOUND; ANTIVIRUS AGENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 6; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; POLYSACCHARIDE; VIRUS ANTIBODY;

AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; CELL EXPANSION; CELL FUNCTION; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; HOST RESISTANCE; HOST SUSCEPTIBILITY; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; INFECTION PREVENTION; INNATE IMMUNITY; LENTINUS EDODES; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MORTALITY; MOUSE; NONHUMAN; PREMEDICATION; SPLEEN; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT DURATION; VIREMIA; VIRUS ENCEPHALITIS; VIRUS INHIBITION; WEST NILE FLAVIVIRUS; ANIMAL; ARTICLE; BLOOD; CHEMISTRY; DRUG EFFECT; FEMALE; IMMUNOLOGY; MALE; ORAL DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION; VIRUS INFECTION;

FUNGI; LENTINULA EDODES; MURINAE; MUS; WEST NILE VIRUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; AGING; ANIMALS; ANTIBODIES, VIRAL; FEMALE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MICE; POLYSACCHARIDES; SHIITAKE MUSHROOMS; T-LYMPHOCYTE SUBSETS; WEST NILE FEVER;

EID: 62749160840     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.108.100297     Document Type: Conference Paper

References (33)

1. Brinton MA. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu Rev Microbiol. 2002;56:371-402.
2. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis. 2002;2:519-29.
3. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med. 2006;57:181-94.
4. Jean CM, Honarmand S, Louie JK, Glaser CA. Risk factors for West Nile virus neuroinvasive disease, California, 2005. Emerg Infect Dis. 2007;13:1918-20.
5. Beasley DW, Li L, Suderman MT, Barrett AD. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology. 2002;296:17-23.
6. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol. 2003;77:2578-86.
7. Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis. 2002;8:107-8.
8. Lucas M, Mashimo T, Frenkiel MP, Simon-Chazottes D, Montagutelli X, Ceccaldi PE, Guenet JL, Despres P. Infection of mouse neurones by West Nile virus is modulated by the interferon-inducible 2′-5′ oligoadenylate synthetase 1b protein. Immunol Cell Biol. 2003;81: 230-6.
9. Wang T, Scully E, Yin Z, Kim JH, Wang S, Yan J, Mamuia M, Anderson JF, Craft J, et al. IFN-gamma-producing gammadelta T cells help control murine West Nile virus infection. J Immunol. 2003;171:2524-31.
10. Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair CD. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sei. 2001;951:286-97.
11. Arjona A, Foellmer HG, Town T, Leng L, McDonald C, Wang T, Wong SJ, Montgomery RR, Fikrig E, et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest. 2007;117:3059-66.
12. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med. 2004;10:1366-73.
13. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 2000;5:4-27.
14. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002;37:78-86.
15. Matsushita K, Kuramitsu Y, Ohiro Y, Obara M, Kobayashi M, Li YQ, Hosokawa M. Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anticancer Drugs. 1998;9:343-50.
16. Burikhanov RB, Wakame K, Igarashi Y, Wang S, Matsuzaki S. Suppressive effect of active hexose correlated compound (AHCC) on thymic apoptosis induced by dexamethasone in the rat. Endocr Regul. 2000;34:181-8.
17. Yagita A, Maruyama S, Wakasugi S, Sukegawa Y. H-2 haplotype-dependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts. In Vivo. 2002;16:49-54.
18. Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immun-other. 2006;55:1258-66.
19. Daddaoua A, Martinez-Plata E, Lopez-Posadas R, Vieites JM, Gonzalez M, Requena P, Zarzuelo A, Suarez MD, de Medina FS, et al. Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis. J Nutr. 2007;137:1222-8.
20. Ritz BW, Nogusa S, Ackerman EA, Gardner EM. Supplementation with active hexose correlated compound increases the innate immune response of young mice to primary influenza infection. J Nutr. 2006;136: 2868-73.
21. Aviles H, Belay T, Fountain K, Vance M, Sun B, Sonnenfeld G. Active hexose correlated compound enhances resistance to Klebsiella pneumo-niae infection in mice in the hindlimb-unloading model of spaceflight conditions. J Appl Physiol. 2003;95:491-6.
22. Weite T, Lamb J, Anderson JF, Born WK, O'Brien RL, Wang T. Role of two distinct gammadelta T cell subsets during West Nile virus infection. FEMS Immunol Med Microbiol. 2008;53:275-83.
23. Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, Komar N, Panella NA, Allen BC, et al. Rapid detection of West Nile virus from human clinical specimens, fieldcollected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol. 2000;38:4066-71.
24. Wang S, Weite T, McGargill M, Town T, Thompson J, Anderson JF, Flavell RA, Fikrig E, Hedrick SM, et al. Drak2 contributes to West Nile virus entry into the brain and lethal encephalitis. J Immunol. 2008;181:2084-91.
25. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med. 2003;198:1853-62.
26. Wang T, Fikrig E. Immunity to West Nile virus. Curr Opin Immunol. 2004;16:519-23.
27. Nair PK, Melnick SJ, Ramachandran R, Escalon E, Ramachandran C. Mechanism of macrophage activation by (1,4)-alpha-D-glucan isolated from Tinospora cordifolia. Int Immunopharmacol. 2006;6:1815-24.
28. Bittencourt VC, Figueiredo RT, da Silva RB, Mourao-Sa DS, Fernandez PL, Sassaki GL, Mulloy B, Bozza MT, Barreto-Bergter E. An alpha-glucan of Pseudallescheria boydii is involved in fungal phagocytosis and Toll-like receptor activation. J Biol Chem. 2006;281:22614-23.
29. Burns EA. Effects of aging on immune function. J Nutr Health Aging. 2004;8:9-18.
30. Zagozdzon R, Foroncewicz B, Paczek L. The aging of the immune system. Przegl Lek. 2003;60:156-60.
31. FDA. Guidance for industry and reviewers: estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Rockville (MD): U.S. Department of Health and Human Services; 2002. p. 18-21.
32. Spierings EL, Fujii H, Sun B, Walshe TA. Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. J Nutr Sei Vitaminol (Tokyo). 2007;53:536-9.
33. Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, et al. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial. Nutr Cancer. 2008;60:643-51.